Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

[1]  Erika Martinelli,et al.  Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. , 2011, Lung cancer.

[2]  J. Brunet,et al.  Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells , 2011, Journal of cellular biochemistry.

[3]  M. Santoro,et al.  Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells , 2010, Clinical Cancer Research.

[4]  I. Fidler,et al.  AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.

[5]  R. Govindan,et al.  Annual Review of Advances in Lung Cancer Clinical Research: A Report for the Year 2009 , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  N. Munshi,et al.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo , 2010, British journal of haematology.

[7]  E. Giovannetti,et al.  A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[8]  J. Vandesompele,et al.  Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Jänne,et al.  Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance , 2009, Clinical Cancer Research.

[10]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[11]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[12]  P. Jänne,et al.  Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers , 2008, Clinical Cancer Research.

[13]  A. Ryan,et al.  Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells , 2008, Clinical Cancer Research.

[14]  Stuart Thomson,et al.  Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy , 2008, Clinical & Experimental Metastasis.

[15]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[16]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[17]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[18]  S. Thomson,et al.  Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions , 2008, Clinical & Experimental Metastasis.

[19]  G. Tortora,et al.  Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. , 2007, Differentiation; research in biological diversity.

[20]  Chun-you Wang,et al.  Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. , 2007, The Journal of surgical research.

[21]  P. Bunn,et al.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma , 2007, Molecular Cancer Therapeutics.

[22]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[23]  Giovanni Parmigiani,et al.  Pre-processing Agilent microarray data , 2007, BMC Bioinformatics.

[24]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[25]  J. Haley,et al.  Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition , 2007, Molecular Cancer Therapeutics.

[26]  C. Dinney,et al.  Molecular correlates of gefitinib responsiveness in human bladder cancer cells , 2007, Molecular Cancer Therapeutics.

[27]  Edward S. Kim,et al.  Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. , 2006, Cancer research.

[28]  P. Smolewski.  Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway , 2006, Anti-cancer drugs.

[29]  G. Giaccone,et al.  Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. , 2006, International journal of cancer.

[30]  D. Hicklin,et al.  Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy , 2006, Clinical Cancer Research.

[31]  C. Yiannoutsos,et al.  Autocrine activation of PDGFRα promotes the progression of ovarian cancer , 2006, Oncogene.

[32]  G. Cavet,et al.  Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.

[33]  R. Price,et al.  Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. , 2005, Journal of the National Cancer Institute.

[34]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[36]  M. Kuwano,et al.  Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.

[37]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[38]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[39]  N. Normanno,et al.  Vandetanib: An overview of its clinical development in NSCLC and other tumors. , 2010, Drugs of today.

[40]  C. Yiannoutsos,et al.  Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. , 2006, Oncogene.

[41]  D. Auclair,et al.  Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor , 2004 .